Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.155 CAD | +3.33% | +14.81% | +93.75% |
26/03 | Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
25/03 | Marvel Biosciences Announces Positive Interim Results For MB-204 | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.18M 4.38M 266M |
---|---|---|---|---|---|
Net income 2022 | -2M -2.75M -167M | Net income 2023 | -2M -2.75M -167M | EV / Sales 2022 | - |
Net cash position 2022 | 593K 816K 49.5M | Net Debt 2023 | 443K 610K 37M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.09
x | P/E ratio 2023 |
-1.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.15% |
1 day | +3.33% | ||
1 week | +14.81% | ||
Current month | +3.33% | ||
1 month | -3.12% | ||
3 months | +47.62% | ||
6 months | +121.43% | ||
Current year | +93.75% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Matheson
CEO | Chief Executive Officer | - | 14/21/14 |
Harry Nijjar
DFI | Director of Finance/CFO | 36 | 01/22/01 |
Mark Williams
PSD | President | 52 | 14/21/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
S. Smallbone
BRD | Director/Board Member | - | 15/22/15 |
Joseph Matheson
CEO | Chief Executive Officer | - | 14/21/14 |
Mark Williams
PSD | President | 52 | 14/21/14 |
Date | Price | Change | Volume |
---|---|---|---|
01/24/01 | 0.155 | +3.33% | 10 050 |
29/24/29 | 0.15 | +3.45% | 10,500 |
26/24/26 | 0.145 | +7.41% | 158,571 |
25/24/25 | 0.135 | 0.00% | 4,000 |
24/24/24 | 0.135 | 0.00% | 6,024 |
Delayed Quote Toronto S.E., April 01, 2024 at 12:53 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+93.75% | 4.37M | |
+0.35% | 42.86B | |
+11.63% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.41% | 25.15B | |
-24.17% | 18.63B | |
+27.53% | 12.37B | |
-3.22% | 11.92B | |
+6.92% | 11.21B |
- Stock Market
- Equities
- MRVL Stock